Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Pierre Caloz was terminated as Chief Operating Officer at uniQure N.V..
- Action
- terminated
- Role
- Chief Operating Officer
Exact text from the filing
In connection with the closing of the Lexington Transaction, on July 22, 2024, the Company notified Pierre Caloz, the Company’s Chief Operating Officer, that his employment was being terminated consistent with the terms of the employment agreement by and between uniQure biopharma B.V. and Mr. Caloz, dated May 17, 2021.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.95
uniQure N.V. completed a disposition involving Genezen MA, Inc. and Genezen Holdings, Inc. for shares of newly issued Series C preferred stock of Genezen Holdings valued at $12.5 million...and a $12.5 million convertible promissory note (closed 2024-07-22).
- Action
- disposition
- Counterparty
- Genezen MA, Inc. and Genezen Holdings, Inc.
- Consideration
- shares of newly issued Series C preferred stock of Genezen Holdings valued at $12.5 million...and a $12.5 million convertible promissory note
- Closing
- 2024-07-22
Exact text from the filing
(the “ Lexington Transaction ”). At the closing of the Lexington Transaction, uniQure received (i) shares of newly issued Series C preferred stock of Genezen Holdings valued at $12.5 million, which are convertible into Genezen Holdings common stock and accrue an 8% per annum cumulative dividend, and (ii) a $12.5 million convertible promissory note from Genezen
View on SEC.gov